{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:52:21Z","timestamp":1782255141074,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,6,20]],"date-time":"2015-06-20T00:00:00Z","timestamp":1434758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2015,6,20]],"date-time":"2015-06-20T00:00:00Z","timestamp":1434758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s10637-015-0261-3","type":"journal-article","created":{"date-parts":[[2015,6,19]],"date-time":"2015-06-19T08:00:45Z","timestamp":1434700845000},"page":"1040-1047","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors"],"prefix":"10.1007","volume":"33","author":[{"given":"Matthew","family":"Zibelman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ning","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Devarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lois","family":"Malizzia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alycia","family":"Corrigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Olszanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal S.","family":"Denlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan K.","family":"Roethke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen H.","family":"Tetzlaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Plimack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,20]]},"reference":[{"issue":"8","key":"261_CR1","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1038\/sj.bjc.6602162","volume":"91","author":"S Chan","year":"2004","unstructured":"Chan S (2004) Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 91(8):1420\u20131424","journal-title":"Br J Cancer"},{"issue":"7092","key":"261_CR2","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/nature04869","volume":"441","author":"RJ Shaw","year":"2006","unstructured":"Shaw RJ, Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441(7092):424\u2013430","journal-title":"Nature"},{"issue":"2","key":"261_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0092-8674(00)00117-3","volume":"103","author":"T Schmelzle","year":"2000","unstructured":"Schmelzle T, Hall MN (2000) TOR, a central controller of cell growth. Cell 103(2):253\u2013262","journal-title":"Cell"},{"issue":"1","key":"261_CR4","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.juro.2006.08.076","volume":"177","author":"VA Robb","year":"2007","unstructured":"Robb VA et al (2007) Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol 177(1):346\u2013352","journal-title":"J Urol"},{"issue":"5 Suppl 16","key":"261_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0093-7754(01)90290-8","volume":"28","author":"GB Mills","year":"2001","unstructured":"Mills GB et al (2001) The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol 28(5 Suppl 16):125\u2013141","journal-title":"Semin Oncol"},{"issue":"1","key":"261_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1091\/mbc.7.1.25","volume":"7","author":"NC Barbet","year":"1996","unstructured":"Barbet NC et al (1996) TOR controls translation initiation and early G1 progression in yeast. Mol Biol Cell 7(1):25\u201342","journal-title":"Mol Biol Cell"},{"issue":"16","key":"261_CR7","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1101\/gad.1212704","volume":"18","author":"N Hay","year":"2004","unstructured":"Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev 18(16):1926\u20131945","journal-title":"Genes Dev"},{"issue":"13","key":"261_CR8","first-page":"4641","volume":"9","author":"AJ Pantuck","year":"2003","unstructured":"Pantuck AJ et al (2003) Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 9(13):4641\u20134652","journal-title":"Clin Cancer Res"},{"issue":"1","key":"261_CR9","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nm1337","volume":"12","author":"GV Thomas","year":"2006","unstructured":"Thomas GV et al (2006) Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12(1):122\u2013127","journal-title":"Nat Med"},{"issue":"22","key":"261_CR10","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271\u20132281","journal-title":"N Engl J Med"},{"issue":"9637","key":"261_CR11","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449\u2013456","journal-title":"Lancet"},{"issue":"31","key":"261_CR12","doi-asserted-by":"publisher","first-page":"27975","DOI":"10.1074\/jbc.M204152200","volume":"277","author":"C Treins","year":"2002","unstructured":"Treins C et al (2002) Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase\/target of rapamycin-dependent signaling pathway. J Biol Chem 277(31):27975\u201327981","journal-title":"J Biol Chem"},{"issue":"13","key":"261_CR13","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1128\/MCB.25.13.5675-5686.2005","volume":"25","author":"RR Raval","year":"2005","unstructured":"Raval RR et al (2005) Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25(13):5675\u20135686","journal-title":"Mol Cell Biol"},{"issue":"3","key":"261_CR14","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#","volume":"22","author":"SC Clifford","year":"1998","unstructured":"Clifford SC et al (1998) Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosom Cancer 22(3):200\u2013209","journal-title":"Genes Chromosom Cancer"},{"issue":"S10","key":"261_CR15","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1002\/cncr.24239","volume":"115","author":"GR Hudes","year":"2009","unstructured":"Hudes GR (2009) Targeting mTOR in renal cell carcinoma. Cancer 115(S10):2313\u20132320","journal-title":"Cancer"},{"issue":"3","key":"261_CR16","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O\u2019Reilly","year":"2006","unstructured":"O\u2019Reilly KE et al (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66(3):1500\u20131508","journal-title":"Cancer Res"},{"issue":"11","key":"261_CR17","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1158\/1078-0432.CCR-07-4306","volume":"14","author":"HM Verheul","year":"2008","unstructured":"Verheul HM et al (2008) Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res 14(11):3589\u20133597","journal-title":"Clin Cancer Res"},{"issue":"9","key":"261_CR18","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","volume":"5","author":"JE Bolden","year":"2006","unstructured":"Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5(9):769\u2013784","journal-title":"Nat Rev Drug Discov"},{"issue":"17","key":"261_CR19","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","volume":"23","author":"WK Kelly","year":"2005","unstructured":"Kelly WK et al (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23(17):3923\u20133931","journal-title":"J Clin Oncol"},{"issue":"2","key":"261_CR20","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejphar.2007.06.015","volume":"571","author":"H Matsuoka","year":"2007","unstructured":"Matsuoka H et al (2007) Mechanisms of HDAC inhibitor-induced thrombocytopenia. Eur J Pharmacol 571(2):88\u201396","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"261_CR21","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1200\/JCO.2007.12.0345","volume":"26","author":"MM Mita","year":"2008","unstructured":"Mita MM et al (2008) Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5\u00a0days every 2\u00a0weeks to patients with advanced malignancies. J Clin Oncol 26(3):361\u2013367","journal-title":"J Clin Oncol"},{"issue":"14","key":"261_CR22","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1182\/blood-2009-05-220889","volume":"114","author":"M Gupta","year":"2009","unstructured":"Gupta M et al (2009) Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood 114(14):2926\u20132935","journal-title":"Blood"},{"key":"261_CR23","doi-asserted-by":"crossref","unstructured":"Morgan S, Cranmer L Effect of the combination of mTOR inhibitor ridaforolimus and HDAC inhibitor vorinostat on in vitro synergism in synovial sarcoma, osteosarcoma, and a range of other tumor subtypes. In Journal Of Clinical Oncology. 2011. Amer Soc Clinical Oncology 2318 mill road, STE 800, Alexandria, VA 22314 USA.","DOI":"10.1200\/jco.2011.29.15_suppl.10080"},{"issue":"9","key":"261_CR24","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.lfs.2010.12.017","volume":"88","author":"S Wedel","year":"2011","unstructured":"Wedel S et al (2011) Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001. Life Sci 88(9):418\u2013424","journal-title":"Life Sci"},{"issue":"2","key":"261_CR25","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/j.1541-0420.2006.00685.x","volume":"63","author":"X Huang","year":"2007","unstructured":"Huang X et al (2007) A parallel phase I\/II clinical trial design for combination therapies. Biometrics 63(2):429\u2013436","journal-title":"Biometrics"},{"key":"261_CR26","unstructured":"Confidential Investigators Brochure: Vorinostat, I. Merck and Co., Editor"},{"issue":"2","key":"261_CR27","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s12032-009-9177-0","volume":"26","author":"JP Dutcher","year":"2009","unstructured":"Dutcher JP et al (2009) Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 26(2):202\u2013209","journal-title":"Med Oncol"},{"issue":"12","key":"261_CR28","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/j.humpath.2012.01.009","volume":"43","author":"A Chaux","year":"2012","unstructured":"Chaux A et al (2012) Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas. Hum Pathol 43(12):2129\u20132137","journal-title":"Hum Pathol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0261-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-015-0261-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0261-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0261-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:45:56Z","timestamp":1678509956000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-015-0261-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,20]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["261"],"URL":"https:\/\/doi.org\/10.1007\/s10637-015-0261-3","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,20]]},"assertion":[{"value":"30 April 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}